Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

Brief summary

The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1. induces immune responses comparable to that produced by the current manufacturing process 2. has an acceptable safety profile compared to a licensed trivalent seasonal influenza vaccine 3. demonstrates consistency of immune response among three different lots.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

COMPLETED

phase

PHASE3

study type

INTERVENTIONAL

enrollment

1928

sponsor

Alachua Government Services, Inc.

conditions

Influenza

interventions

BIOLOGICAL: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified); BIOLOGICAL: VCIV manufactured with the current manufacturing process (VCIV current); BIOLOGICAL: Fluzone®, licensed trivalent influenza vaccine (TIV)

start date

2013-01-01

primary completion date

2013-04-01

has results

true

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters